Fludarabine is considered the treatment of choice for most patients with chronic lymphocytic leukemia (CLL). We have analyzed the role of plasma membrane transporters in nucleoside-derived drug bioavailability and action in CLL cells. Among the known plasma membrane transporters, we have previously observed a significant correlation between fludarabine uptake via ENT carriers and ex vivo sensitivity of CLL cells to fludarabine, although mRNA amounts of the equilibrative nucleoside transporters hENT1 and hENT2 do not show any predictive response to treatment. In this study, using polyclonal monospecific antibodies we have observed a significant correlation between the expression of hENT2 by Western blot and fludarabine uptake via hENT carriers and also with ex vivo sensitivity of CLL cells to fludarabine. These results suggest that the equilibrative nucleoside transporter hENT2 plays a role in fludarabine responsiveness in CLL patients.
Introduction
B-cell chronic lymphocytic leukemia (CLL) is characterized by the accumulation of long-lived, functionally inactive, mature appearing, neoplastic B lymphocytes. 1 The clonal excess of B cells is mainly caused by a decrease in cell death rather than by increased cell proliferation. 2 CLL is currently an incurable disease but several drug therapies, including the purine analog fludarabine, are now known to cause clinical improvement in CLL patients. 3 Several in vitro studies indicate that in CLL cells fludarabine induces apoptosis, suggesting that programmed cell death is the mechanism of their therapeutic action. [4] [5] [6] [7] [8] [9] As CLL cells are predominantly quiescent cells, the proapoptotic activity of fludarabine could be due to inhibition of RNA synthesis or alteration of DNA repair. Both p53-dependent and -independent mechanisms have been described. 10, 11 Anticancer therapy using nucleoside-derived analogs is dependent on drug uptake and metabolic activation. Although some enzymes are suitable biomarkers of drug metabolism and may determine response to therapy, [12] [13] [14] the role of transporters in determining nucleoside-derived drug bioavailability is less well known. The uptake of these drugs into cells is mediated by one or more of the nucleoside transporters (NT), which have recently been cloned. These proteins belong to two nonrelated gene families, SLC28 and SLC29, encoding CNT (concentrative nucleoside transporters) and ENT (equilibrative nucleoside transporters) proteins, respectively. 15, 16 Leukemia cells appear to express both CNT-and ENT-type transporter mRNAs. 17 Primary CLL cells express hENT1, hENT2, hCNT2 and hCNT3. hCNT3 and hCNT2 are high-affinity Na þ -dependent NT showing broad selectivity and purine preference, respectively. hENT1 and hENT2 are broad-selectivity equilibrative carrier proteins, the former showing high sensitivity to pharmacological inhibition by the adenosine analog NBTI. Despite the apparent co-expression of at least these four transporter genes in CLL cells, most of the measurable natural nucleoside transport and all detectable fludarabine uptake into CLL cells rely on hENT-type carriers. 18 Clinical correlations using the pattern of NT isoform expression have recently been obtained when monitoring NT occurrence in nearly 300 gynecological tumors using a tissue array approach. hENT1 and hENT2 expression was significantly retained in a high percentage of tumors, whereas hCNT1 expression was frequently reduced or lost, 19 particularly in some histotypes characterized by poor prognosis. Similarly, in a previous study using a small cohort of breast-cancer patients, only a few tumors were found to be negative for hENT1, 20 thus suggesting that, although hENT1 expression might show variability among tumors, a complete lack of hENT1 protein may be rare.
In hematological malignances, a significant correlation between mRNA levels and ara-C-induced cytotoxicity has been reported in acute myeloid leukemia. 21 Nevertheless, in CLL patients, although they show high mRNA levels for hENT1 and hENT2, mRNA amounts do not correlate with ex vivo sensitivity to fludarabine, whereas fludarabine influx does. 18 However, uptake measurements may not be a suitable tool to predict response to treatment in CLL because this technique is complex: it requires the use of radioactive-labeled drug, as well as a large number of cells. Since the closest measurable parameter to influx rates is the determination of transporter protein amounts, we have recently used characterized polyclonal monospecific antibodies to establish, firstly, whether protein levels associate with substrate influx and cytotoxicity, and secondly, which particular isoform can predict response to treatment.
Materials and methods

Patients
Cells from 21 patients with CLL who had not been previously treated with fludarabine were included in the study. The diagnosis was established according to the World Health Organization classification. 22 In all patients, informed consent was obtained at the time of diagnosis from Hospital Clinic.
Isolation and culture of cells
Mononuclear cells were isolated from blood using gradient centrifugation with Ficoll/Hypaque (Seromed, Berlin, Germany). These cells were more than 95% positive for CD19 and CD5, as assessed by flow cytometry. Cells were used either immediately or after thawing cryopreserved samples.
Cell viability assay
CLL lymphocytes (5 Â 10 5 cells/well) were incubated in 96-well plates in the absence or presence of fludarabine (3, 7.5 and 15 mM) (Schering; Berlin, Germany) in a final volume of 100 ml. Cell viability was determined at 48 h by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay as previously described.
4,18
Western blot analysis
For the analysis of hENT1 expression, protein extracts were obtained as previously described. 23 Briefly, cells were lysed in 20 mM Tris (tris-hydroxymethyl-aminomethane)-HCl, pH 7.5; 0.3 M saccharose; 2 mM EGTA (ethylene glycol-bis-(b-amioethylether) N,N,N 0 ,N 0 -tetraacetic acid); 2 mM EDTA (ethylenediaminetetraacetic acid); 10 mM 2-mercapto-ethanol; 1 mM PMSF; 0.01 mg/ml leupeptin; 0.5% aprotinin; 1% Nonidet P-40. After sonication three times for 10 s, cells were centrifuged at 14 000 rpm for 30 min at 41C. The remaining pellets were lysed with the same buffer plus 0.15% Nonidet P-40 and 3 mM EGTA, incubated on ice for 30 min, sonicated again and centrifuged. Pellets were lysed in 80 mM Tris-HCl, pH 6.8; 2% sodium dodecyl sulfate (SDS); 10% glycerol; 0.1 M DTT (dithiothreitol). Protein extracts for hENT2 analysis were obtained using 10 mM Tris-HCl (pH 7.4), 0.5% Triton X-100, as described. 24 Proteins were separated on 10% SDS polyacrylamide gels, and transferred onto Immobilon-P (Millipore, Bedford, MA, USA) membranes.
Monospecific polyclonal antibodies against hENT1 and hENT2 have recently been characterized. 19 They were raised against isoform-specific domains at the intracellular loop between transmembrane domains 6 and 7. Following incubations with these primary antibodies against hENT1 and hENT2, proteins were detected with the use of secondary antibodies conjugated to horseradish peroxidase and an enhanced chemiluminiscence (ECL) detection kit (Amersham, Buckinghamshire, UK). Protein loading was confirmed with a-tubulin (Oncogene Research, Boston, MA, USA).
Real-time quantitative RT-PCR
Total RNA was isolated using the guanidinium thiocyanate method (Ultraspec, Bioteck laboratories, Houston, TX, USA). RNA was treated with DNAse (Ambion, Austin, TX, USA) to eliminate contaminating DNA. In total, 1 mg of RNA was retrotranscribed to cDNA using the Taqman reverse transcription reagents as previously described. 18 Real time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of hENT1, hENT2 and human b-glucoronidase (GUS) mRNA was performed as previously described. 18 Relative quantification of gene expression was performed as described in the TaqMan user's manual using GUS as an internal control.
Nucleoside transport
Nucleoside transport into CLL cells was measured using a rapid filtration method, as previously described.
18 H]guanosine and [8- 3 H]fludarabine (Moravek Biochemicals) were used as substrates at a concentration of 1 mM. Incubation time was 10 s.
Statistical analysis
Correlations between nucleoside transporter expression, nucleoside transport and fludarabine-induced cytotoxicity were analyzed using SPSS 10.0 software package (SPSS, Chicago, IL, USA). Significance of the correlation was assessed by Pearson test.
Results
hENT1 and hENT2 mRNA expression in patients with CLL Figure 1 shows the amount of hENT1 (a) and hENT2 (b) mRNAs in cells from 21 CLL patients. The expression of each nucleoside transporter in one representative CLL patient was used as a relative calibrator and the expression levels of these cells were assigned the value of 1 as an arbitrary unit. Although a high variability in each transporter was detected, hENT1 mRNA expression showed highest variation than hENT2. Whereas Figure 1 mRNA expression levels of nucleoside transporters in CLL cells. Normalized hENT1 (a) and hENT2 (b) mRNA expression levels in the cohort of CLL-patients analyzed. C T values for each nucleoside transporter from CLL cDNA samples have been normalized to an endogenous reference gene (GUS). mRNA expression levels are given in arbitrary units, using one CLL cDNA sample as reference control.
hENT2 mRNA levels showed a range of variability of nearly four-fold, and hENT1 variability was 19-fold.
Equilibrative nucleoside transporter expression pattern in CLL cells
The expression of NT hENTs was analyzed by Western blot in CLL samples. As recently reported 19 these antibodies specifically recognized single bands of 50-55 kDa in CLL protein extracts. Figure 2 shows representative Western blots of five independent CLL samples in which hENT1 (a), hENT2 (b) and atubulin were analyzed. Antibodies against hENT1 and hENT2 consistently identified a single band of 50-55 kDa in all samples. Western blot using different quantities of protein showed that hENT1 and hENT2 densitometric signals were lineal up to 70 mg of loaded protein (data not shown).
Densitometric analysis of blot was carried out using Phoretix 1D Software. Semiquantitative analysis of hENT1 and hENT2 expression was achieved by calculating the densitometry ratios vs a-tubulin, in a range of protein concentrations in which densitometric signal has been previously shown to be linear. Similar results were obtained when actin was used as a constitutive control (not shown). The expression of hENT1 and hENT2 in one CLL case was used as a relative calibrator and the expression level of these cells were assigned the value of 1 as an arbitrary unit. Figure 3 shows the values of hENT1 and hENT2 for the whole cohort of CLL patients analyzed in this study. Contrary to the mRNA expression of hENT1 and hENT2, Western blots analysis show that inter-patient variation of hENT2 expression is 11-fold, whereas for hENT1 expression is three-fold.
Correlation of hENT expression with mRNA expression, transporter function and ex vivo fludarabine cytotoxicity
The amounts of hENT1 protein did not correlate significantly with hENT1 mRNA expression, determined by real time RT-PCR, or transporter function, or ex vivo fludarabine cytotoxicity (not shown). In contrast, although hENT2 protein did not show any significant relationship with hENT2 mRNA amounts in CLL patients (Figure 4a ), it correlated with transport activity when either a natural nucleoside (guanosine) (Figure 4b ) or fludarabine (Figure 4c ) was the substrate. This close relationship between protein and function extended to cytotoxicity itself, as shown in Figure 4d . Ex vivo sensitivity to fludarabine, at a pharmacological concentration (7.5 mM), directly correlated with the amount of hENT2 protein. Similar correlations were observed when the drug was tested at 3 and 15 mM (not shown).
Discussion
The role of nucleoside-derived transporters in modulating drug bioavailability in lymphoid cells has been addressed by analyzing how the pharmacological inhibition of the hENT1 transporter by NBTI modifies drug sensitivity, depending on whether the inhibitor is added either before or after in vitro nucleoside treatment. Although ENT proteins may indeed facilitate transport in both directions depending on the relative transmembrane substrate gradient, it has been reported that blocking of hENT1 results either in increased retention and cytotoxicity of cladribine in cells from CLL patients 25 and in cultured human leukemic lymphoblasts, 26 or, alternatively, inhibition of acadesine-induced apoptosis due to the blockade of acadesine entry into CLL cells. 27 Similarly, high-affinity binding of NBTI has been used to monitor hENT1-type binding sites at the membrane surface and has been shown to correlate with sensitivity to citarabine. 28 Nevertheless, the lack of appropriate molecular tools (ie cDNAs, antibodies) has been a bottleneck in the analysis of cytotoxicity associated with specific nucleoside transporter isoforms. This is particularly relevant for hENT2, for which no specific ligands are known and, to date, no hENT1 and hENT2 protein expression in CLL cells. Normalized hENT1 (a) and hENT2 (b) protein expression levels in the cohort of CLL-patients analyzed. Protein amounts were calculated as the densitometric ratio of hENT vs a-tubulin, and were given as arbitrary units using one CLL sample as reference control. proof that hENT2 has a role in nucleoside-derived cytotoxicity has yet been reported. In this study we show a lack of correlation between the amount of hENT proteins and their corresponding mRNA levels, as determined by real time RT-PCR. This agrees with previous observations, 18 showing that hENT-mediated accumulation of fludarabine into CLL cells does not correlate with mRNA amounts. However, the evidence that transporter function reflects ex vivo fludarabine cytotoxicity prompted us to attempt to identify the particular transporter isoform(s) responsible. This is a relevant issue because it incorporates a new biomarker of nucleotide metabolism as a predictive agent of response to treatment.
Interestingly, the total amount of hENT1 protein does not correlate with either fludarabine uptake or ex vivo cytotoxicity. Total hENT1 protein may not reflect function, since it has been reported that hENT1 can be located intracellularly 29, 30 and hENT1 related transport activity is also under post-translational control via Protein kinase C. 31 However, this observation might also be explained by the fact that fludarabine uptake measurements, at least in our hands, do not discriminate between hENT1-and hENT2-mediated uptake processes. Nevertheless, fludarabine is also an hENT2 substrate 13 and, according to our data, hENT2 alone seems to predict ex vivo sensitivity to the drug. This is based upon the fact that, irrespective of the contribution of hENT1 in transport function, fludarabine uptake rates significantly correlate with hENT2 protein amounts and transporter protein also shows a significant correlation with the ex vivo sensitivity to the drug, when used at a variety of pharmacologically relevant concentrations. The possibility that hENT1-related transport activity, rather than hENT2 function, is under complex post-translational control, involving either translocation into the membrane or phosphorylation-dependent processes, will require further research.
In summary, this study strongly indicates that fludarabine action on CLL cells is determined by the equilibrative nucleoside transporter hENT2. This is the first time hENT2 has been implicated in the therapeutic response to a nucleoside analog and these findings might be used to predict fluradabine response in CLL patients. Whether this applies to other lymphoproliferative diseases will require further research. Correlations between hENT2 protein and mRNA, nucleoside transport activities and ex vivo fludarabine cytotoxicity. Human ENT2 protein expression levels were plotted against (a) hENT2 mRNA amounts, (b) guanosine uptake rates (10 s, 1 mM), (c) fludarabine uptake rates (10 s, 1 mM), and (d) ex vivo sensitivity to fludarabine, expressed as percentage of non viable cells after 48 h treatment with 7.5 mM fludarabine, assessed by the MTT assay. Correlation coefficients and P-values are shown in inboxes.
